PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30560837-4 2019 Significantly higher prostate-specific antigen response rate was found in docetaxel-naive group (54.4%, 56/103) compared to docetaxel-resistant group (34.9%, 15/43) (P = 0.047). Docetaxel 74-83 kallikrein related peptidase 3 Homo sapiens 21-46 30560837-4 2019 Significantly higher prostate-specific antigen response rate was found in docetaxel-naive group (54.4%, 56/103) compared to docetaxel-resistant group (34.9%, 15/43) (P = 0.047). Docetaxel 124-133 kallikrein related peptidase 3 Homo sapiens 21-46 30560837-5 2019 In addition, significantly higher median prostate-specific antigen progression-free survival (14.0 vs 7.7 months, P = 0.005), clinical or radiographic progression-free survival (17.0 vs 12.5 months, P = 0.003), and overall survival (27.0 vs 18.0 months, P = 0.016) were found in docetaxel-naive group compared to docetaxel-resistant group, respectively. Docetaxel 279-288 kallikrein related peptidase 3 Homo sapiens 41-66 30560837-5 2019 In addition, significantly higher median prostate-specific antigen progression-free survival (14.0 vs 7.7 months, P = 0.005), clinical or radiographic progression-free survival (17.0 vs 12.5 months, P = 0.003), and overall survival (27.0 vs 18.0 months, P = 0.016) were found in docetaxel-naive group compared to docetaxel-resistant group, respectively. Docetaxel 313-322 kallikrein related peptidase 3 Homo sapiens 41-66 32684578-5 2019 Eleven (45.8%) of the 24 docetaxel-naive patients achieved >50% reduction in PSA level from baseline as opposed to one (4.5%) of the 22 patients previously treated with docetaxel.Eleven (55%) of the 20 Enz-naive patients achieved >50% reduction in PSA level from baseline compared to one (3.8%) of the 26 patients previously treated with Enz. Docetaxel 25-34 kallikrein related peptidase 3 Homo sapiens 248-251 32684578-5 2019 Eleven (45.8%) of the 24 docetaxel-naive patients achieved >50% reduction in PSA level from baseline as opposed to one (4.5%) of the 22 patients previously treated with docetaxel.Eleven (55%) of the 20 Enz-naive patients achieved >50% reduction in PSA level from baseline compared to one (3.8%) of the 26 patients previously treated with Enz. Docetaxel 25-34 kallikrein related peptidase 3 Homo sapiens 77-80 30283980-8 2018 A 30% PSA response to cabazitaxel was achieved in 13 (46.4%) and 7 (36.8%) patients with and without that to docetaxel, respectively. Docetaxel 109-118 kallikrein related peptidase 3 Homo sapiens 6-9 30283980-9 2018 A 30% PSA response to cabazitaxel was achieved in 5 (16.6%) and 7 (41.2%) patients who had treated with less than 10 cycles docetaxel or 10 cycles, respectively. Docetaxel 124-133 kallikrein related peptidase 3 Homo sapiens 6-9 30072309-7 2018 The prostate-specific antigen response rate was 46% in all patients, 53% in chemotherapy-naive subjects, and 31% after docetaxel chemotherapy. Docetaxel 119-128 kallikrein related peptidase 3 Homo sapiens 4-29 31158090-8 2018 PSA response on DOC was lower in group 3 than in other groups (p=0.02) and PSA response on CABA was higher in the second than in the third line (p=0.001). Docetaxel 16-19 kallikrein related peptidase 3 Homo sapiens 0-3 29274813-4 2018 RESULTS: The prostate-specific antigen (PSA) level in the 114 patients receiving DTX was significantly greater than that in the 108 patients receiving ARATA. Docetaxel 81-84 kallikrein related peptidase 3 Homo sapiens 13-44 29722038-5 2018 The clinical and prostate-specific antigen (PSA) response allowed an 8-month delay in docetaxel treatment. Docetaxel 86-95 kallikrein related peptidase 3 Homo sapiens 17-48 30048718-3 2018 The model is shown to recapitulate prostate-specific antigen measurement data from three clinical trials for metastatic castration-resistant prostate cancer patients treated with 1) prednisone, 2) mitoxantrone and prednisone and 3) docetaxel and prednisone. Docetaxel 232-241 kallikrein related peptidase 3 Homo sapiens 35-60 29802777-4 2018 RESULTS: Higher pretreatment serum MMP-7, sFas and prostate-specific antigen (PSA) levels were significantly associated with both docetaxel resistance (P = 0.007, P = 0.001, P < 0.001, respectively) and shorter cancer-specific survival (P < 0.001, P = 0.041, P < 0.001, respectively). Docetaxel 130-139 kallikrein related peptidase 3 Homo sapiens 51-82 30051622-7 2018 Consistently, the prostate-specific antigen response and progression-free survival in docetaxel chemotherapy were worse in cases with prior use of ARAT agents compared with cases without. Docetaxel 86-95 kallikrein related peptidase 3 Homo sapiens 18-43 29946852-8 2018 In patients with much higher serum PSA levels, chemotherapy with carboplatin plus docetaxel should be considered. Docetaxel 82-91 kallikrein related peptidase 3 Homo sapiens 35-38 29274813-6 2018 The PSA response rate, PSA progression-free survival (PFS), and overall survival (OS) during second-line therapy in the DTX group (n = 114) were significantly superior to those for the ARATA group (n = 108; PSA response rate, 42.1% vs. 21.3%; median PSA PFS, 7.2 vs. 4.2 months; median OS, 17.5 vs. 14.5 months). Docetaxel 120-123 kallikrein related peptidase 3 Homo sapiens 4-7 29274813-8 2018 Furthermore, the introduction of DTX was independently associated with improved PSA PFS, but not OS, on multivariate analysis. Docetaxel 33-36 kallikrein related peptidase 3 Homo sapiens 80-83 27919966-4 2016 If PSA remained above 1 mug/l, docetaxel was initiated. Docetaxel 31-40 kallikrein related peptidase 3 Homo sapiens 3-6 29261442-7 2018 On multivariable analysis, achieving a 7-month PSA <= 0.2 ng/mL was more likely with docetaxel, low-volume disease, prior local therapy, and lower baseline PSAs (all P <= .01). Docetaxel 88-97 kallikrein related peptidase 3 Homo sapiens 47-50 29261442-10 2018 The addition of docetaxel increased the likelihood of achieving a PSA <= 0.2 ng/mL at 7 months (45.3% v 28.8% of patients on ADT alone). Docetaxel 16-25 kallikrein related peptidase 3 Homo sapiens 66-69 29261442-13 2018 Adding docetaxel increased the likelihood of a lower PSA and improved survival. Docetaxel 7-16 kallikrein related peptidase 3 Homo sapiens 53-56 29164346-4 2017 The prostate-specific antigen (PSA) response rates to docetaxel in the AA and Enz groups were 40.7 and 43.3%, respectively, with no significant differences in the rates between these two groups. Docetaxel 54-63 kallikrein related peptidase 3 Homo sapiens 4-35 29164346-5 2017 Following the introduction of docetaxel, the median PSA progression-free survival (PFS) and overall survival (OS) in the 114 patients were 7.2 and 17.5 months, respectively. Docetaxel 30-39 kallikrein related peptidase 3 Homo sapiens 52-55 28608931-7 2017 The primary outcome was the response rate to carboplatin/docetaxel chemotherapy, defined according to a decline in prostate-specific antigen that exceeded 50% within 12 weeks of initiating this regimen. Docetaxel 57-66 kallikrein related peptidase 3 Homo sapiens 115-140 27692811-10 2017 Survival also favored patients treated with >= 9 cycles of docetaxel when only patients ending docetaxel because of toxicity or treatment conclusion (22.3 vs. 19.4 months; P = .048, log rank) or patients who achieved a PSA response (22.3 vs. 18.7 months; P = .012, log rank) were evaluated. Docetaxel 62-71 kallikrein related peptidase 3 Homo sapiens 222-225 26991851-0 2016 Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare. Docetaxel 34-43 kallikrein related peptidase 3 Homo sapiens 117-120 26991851-5 2016 Intriguingly, men with steroid intake before the initiation of docetaxel chemotherapy experienced significantly fewer PSA flares. Docetaxel 63-72 kallikrein related peptidase 3 Homo sapiens 118-121 26991851-7 2016 CONCLUSIONS: Our results suggest that de novo steroid co-introduction with docetaxel chemotherapy induces the PSA flare phenomenon. Docetaxel 75-84 kallikrein related peptidase 3 Homo sapiens 110-113 29063869-4 2018 The improvement in overall survival as well as secondary endpoints of prostate-specific antigen (PSA) and time to recurrence when using docetaxel in the metastatic hormone-sensitive state has changed the standard of care for treatment of newly diagnosed de novo metastatic PCa. Docetaxel 136-145 kallikrein related peptidase 3 Homo sapiens 70-101 28905815-0 2018 PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China. Docetaxel 55-64 kallikrein related peptidase 3 Homo sapiens 0-3 28905815-2 2018 In this study, we retrospectively reviewed the data from 71 eligible Chinese patients who received docetaxel chemotherapy from 2009 to 2016 in our hospital and experienced a reduction of prostate-specific antigen (PSA) level >=50% during the treatment and investigated the potential role of time to nadir (TTN) of PSA. Docetaxel 99-108 kallikrein related peptidase 3 Homo sapiens 214-217 29063171-8 2017 In patients with much higher serum PSA levels, chemotherapy with carboplatin plus docetaxel should be considered. Docetaxel 82-91 kallikrein related peptidase 3 Homo sapiens 35-38 28855993-8 2017 Once EZL therapy was initiated, increases in prostate specific antigen (PSA) levels were observed in 3/18 patients (17%) pre-treated with DOC and in 6/20 (30%) who were DOC-naive. Docetaxel 138-141 kallikrein related peptidase 3 Homo sapiens 45-70 28855993-8 2017 Once EZL therapy was initiated, increases in prostate specific antigen (PSA) levels were observed in 3/18 patients (17%) pre-treated with DOC and in 6/20 (30%) who were DOC-naive. Docetaxel 138-141 kallikrein related peptidase 3 Homo sapiens 72-75 28855993-10 2017 An increase in the PSA level was observed in only 1/8 (12%) cases following AA treatment in the DOC-naive group. Docetaxel 96-99 kallikrein related peptidase 3 Homo sapiens 19-22 28171710-0 2017 Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. Docetaxel 194-203 kallikrein related peptidase 3 Homo sapiens 52-77 27995113-5 2016 In the docetaxel therapy, the rate of prostate-specific antigen responses were higher in the DOC group compared with the SHTs-DOC group (76.9% vs. 44.7%, P = 0.0066). Docetaxel 7-16 kallikrein related peptidase 3 Homo sapiens 38-63 26807253-7 2015 The patient was subsequently treated with a combination of docetaxel and octreotide, and a partial response was observed 6 months later, with reduction of the PSA level and the size of the lung metastasis. Docetaxel 59-68 kallikrein related peptidase 3 Homo sapiens 159-162 27057826-2 2016 Although docetaxel is approved in the first-line treatment setting, a few studies have shown that selected patients can benefit from docetaxel rechallenge.We, here, report the case of a heavily pretreated mCRPC patient who reported clinical benefit from receiving docetaxel after previous exposure to docetaxel, cabazitaxel, abiraterone, and enzalutamide.After 4 cycles of treatment, patient"s performance status had improved to 1, the hemoglobin level was 12.9 g/dL and his serum prostate specific antigen levels were reduced by >70%, with no treatment-related adverse events.Although docetaxel rechallenge is a therapeutic option for selected patients, the risk of cumulative toxicity described in literature must be carefully considered.As the risk of cabazitaxel-related cumulative toxicity is probably lower, retreatment with cabazitaxel rather than docetaxel may also be an option in the setting of heavily pretreated mCRPC patients. Docetaxel 9-18 kallikrein related peptidase 3 Homo sapiens 481-506 27057826-2 2016 Although docetaxel is approved in the first-line treatment setting, a few studies have shown that selected patients can benefit from docetaxel rechallenge.We, here, report the case of a heavily pretreated mCRPC patient who reported clinical benefit from receiving docetaxel after previous exposure to docetaxel, cabazitaxel, abiraterone, and enzalutamide.After 4 cycles of treatment, patient"s performance status had improved to 1, the hemoglobin level was 12.9 g/dL and his serum prostate specific antigen levels were reduced by >70%, with no treatment-related adverse events.Although docetaxel rechallenge is a therapeutic option for selected patients, the risk of cumulative toxicity described in literature must be carefully considered.As the risk of cabazitaxel-related cumulative toxicity is probably lower, retreatment with cabazitaxel rather than docetaxel may also be an option in the setting of heavily pretreated mCRPC patients. Docetaxel 133-142 kallikrein related peptidase 3 Homo sapiens 481-506 27057826-2 2016 Although docetaxel is approved in the first-line treatment setting, a few studies have shown that selected patients can benefit from docetaxel rechallenge.We, here, report the case of a heavily pretreated mCRPC patient who reported clinical benefit from receiving docetaxel after previous exposure to docetaxel, cabazitaxel, abiraterone, and enzalutamide.After 4 cycles of treatment, patient"s performance status had improved to 1, the hemoglobin level was 12.9 g/dL and his serum prostate specific antigen levels were reduced by >70%, with no treatment-related adverse events.Although docetaxel rechallenge is a therapeutic option for selected patients, the risk of cumulative toxicity described in literature must be carefully considered.As the risk of cabazitaxel-related cumulative toxicity is probably lower, retreatment with cabazitaxel rather than docetaxel may also be an option in the setting of heavily pretreated mCRPC patients. Docetaxel 133-142 kallikrein related peptidase 3 Homo sapiens 481-506 27057826-2 2016 Although docetaxel is approved in the first-line treatment setting, a few studies have shown that selected patients can benefit from docetaxel rechallenge.We, here, report the case of a heavily pretreated mCRPC patient who reported clinical benefit from receiving docetaxel after previous exposure to docetaxel, cabazitaxel, abiraterone, and enzalutamide.After 4 cycles of treatment, patient"s performance status had improved to 1, the hemoglobin level was 12.9 g/dL and his serum prostate specific antigen levels were reduced by >70%, with no treatment-related adverse events.Although docetaxel rechallenge is a therapeutic option for selected patients, the risk of cumulative toxicity described in literature must be carefully considered.As the risk of cabazitaxel-related cumulative toxicity is probably lower, retreatment with cabazitaxel rather than docetaxel may also be an option in the setting of heavily pretreated mCRPC patients. Docetaxel 133-142 kallikrein related peptidase 3 Homo sapiens 481-506 27057826-2 2016 Although docetaxel is approved in the first-line treatment setting, a few studies have shown that selected patients can benefit from docetaxel rechallenge.We, here, report the case of a heavily pretreated mCRPC patient who reported clinical benefit from receiving docetaxel after previous exposure to docetaxel, cabazitaxel, abiraterone, and enzalutamide.After 4 cycles of treatment, patient"s performance status had improved to 1, the hemoglobin level was 12.9 g/dL and his serum prostate specific antigen levels were reduced by >70%, with no treatment-related adverse events.Although docetaxel rechallenge is a therapeutic option for selected patients, the risk of cumulative toxicity described in literature must be carefully considered.As the risk of cabazitaxel-related cumulative toxicity is probably lower, retreatment with cabazitaxel rather than docetaxel may also be an option in the setting of heavily pretreated mCRPC patients. Docetaxel 133-142 kallikrein related peptidase 3 Homo sapiens 481-506 27057826-2 2016 Although docetaxel is approved in the first-line treatment setting, a few studies have shown that selected patients can benefit from docetaxel rechallenge.We, here, report the case of a heavily pretreated mCRPC patient who reported clinical benefit from receiving docetaxel after previous exposure to docetaxel, cabazitaxel, abiraterone, and enzalutamide.After 4 cycles of treatment, patient"s performance status had improved to 1, the hemoglobin level was 12.9 g/dL and his serum prostate specific antigen levels were reduced by >70%, with no treatment-related adverse events.Although docetaxel rechallenge is a therapeutic option for selected patients, the risk of cumulative toxicity described in literature must be carefully considered.As the risk of cabazitaxel-related cumulative toxicity is probably lower, retreatment with cabazitaxel rather than docetaxel may also be an option in the setting of heavily pretreated mCRPC patients. Docetaxel 133-142 kallikrein related peptidase 3 Homo sapiens 481-506 28799570-0 2016 A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy. Docetaxel 59-68 kallikrein related peptidase 3 Homo sapiens 84-109 27793943-8 2016 Multivariate analysis showed that the predictors of a 50% PSA response were an interval to mCRPC and a docetaxel treatment history, while the predictor of a 30% PSA response was a docetaxel treatment history. Docetaxel 103-112 kallikrein related peptidase 3 Homo sapiens 58-61 28740046-9 2016 Twenty seven (61.4%) patients with docetaxel-naive achieved over 50% reduction of PSA level from baseline, but only 7 (24.1%) in patients previously treated with docetaxel. Docetaxel 35-44 kallikrein related peptidase 3 Homo sapiens 82-85 26261420-4 2015 Response to docetaxel was defined on the basis of prostate-specific antigen levels and imaging criteria. Docetaxel 12-21 kallikrein related peptidase 3 Homo sapiens 50-75 25735199-0 2015 Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report With Docetaxel Chemotherapy Administered Just Before Sipuleucel-T. Docetaxel 143-152 kallikrein related peptidase 3 Homo sapiens 31-56 25903013-11 2015 CONCLUSIONS: Multimodality systemic therapy with docetaxel, bevacizumab, and ADT is feasible and produces PSA responses in men with BCR. Docetaxel 49-58 kallikrein related peptidase 3 Homo sapiens 106-109 25981621-5 2015 The primary outcome measure was the rates of prostate-specific antigen declines 30 and 50%, respectively, with docetaxel. Docetaxel 113-122 kallikrein related peptidase 3 Homo sapiens 45-70 25981621-7 2015 We performed correlation analysis between previous prostate-specific antigen response to abiraterone acetate and subsequent prostate-specific antigen response to docetaxel. Docetaxel 162-171 kallikrein related peptidase 3 Homo sapiens 124-149 25981621-9 2015 Prostate-specific antigen declines 30 and 50% with docetaxel were observed in five patients (33%) and two patients (13%), respectively. Docetaxel 53-62 kallikrein related peptidase 3 Homo sapiens 0-25 25168825-5 2014 After the PSA level gradually started to increase again and reached 27.27 ng/mL in October 2010, the patient was diagnosed with castration-resistant prostate cancer and treated with docetaxel chemotherapy. Docetaxel 182-191 kallikrein related peptidase 3 Homo sapiens 10-13 25862824-8 2015 The log-rank test revealed that prostate specific antigen before docetaxel and prednisolone (<50 ng/ml) and the prostate specific antigen reduction rate (>=30%) were associated with overall survival (P < 0.001 and P < 0.001, respectively). Docetaxel 65-74 kallikrein related peptidase 3 Homo sapiens 32-57 25862824-10 2015 All except two (97.5%) reached 30% prostate specific antigen reduction within five cycles of docetaxel and prednisolone. Docetaxel 93-102 kallikrein related peptidase 3 Homo sapiens 35-60 25726498-8 2015 CONCLUSIONS: PSA kinetic parameters measured during prior ADT are significant surrogate markers predicting CSS in patients undergoing DCT chemotherapy for CRPC. Docetaxel 134-137 kallikrein related peptidase 3 Homo sapiens 13-16 25043536-0 2014 KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment. Docetaxel 156-165 kallikrein related peptidase 3 Homo sapiens 0-4 24947139-2 2015 PATIENTS AND METHODS: We retrospectively reviewed the records of consecutive patients with mCRPC with a good response to first-line docetaxel [serum prostate specific antigen (PSA) decrease >=50%; no clinical/radiological progression]. Docetaxel 132-141 kallikrein related peptidase 3 Homo sapiens 176-179 24947139-9 2015 However, good PSA response and symptom relief/stable disease were more frequent on docetaxel rechallenge (40.4% vs 10.6%, P < 0.001 for PSA). Docetaxel 83-92 kallikrein related peptidase 3 Homo sapiens 14-17 24947139-9 2015 However, good PSA response and symptom relief/stable disease were more frequent on docetaxel rechallenge (40.4% vs 10.6%, P < 0.001 for PSA). Docetaxel 83-92 kallikrein related peptidase 3 Homo sapiens 139-142 25683983-0 2015 Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer. Docetaxel 109-118 kallikrein related peptidase 3 Homo sapiens 20-51 25683983-0 2015 Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer. Docetaxel 109-118 kallikrein related peptidase 3 Homo sapiens 47-50 25175831-9 2014 The overall PSA response rate to docetaxel was 34.9%, median PFS was 4.0 months and median OS was 11.66 months. Docetaxel 33-42 kallikrein related peptidase 3 Homo sapiens 12-15 25175831-11 2014 Importantly, PSA response rates to docetaxel were comparable in the docetaxel-experienced and docetaxel-naive cohorts and were not linked to prior response to abiraterone in either group. Docetaxel 35-44 kallikrein related peptidase 3 Homo sapiens 13-16 25175831-11 2014 Importantly, PSA response rates to docetaxel were comparable in the docetaxel-experienced and docetaxel-naive cohorts and were not linked to prior response to abiraterone in either group. Docetaxel 68-77 kallikrein related peptidase 3 Homo sapiens 13-16 25175831-11 2014 Importantly, PSA response rates to docetaxel were comparable in the docetaxel-experienced and docetaxel-naive cohorts and were not linked to prior response to abiraterone in either group. Docetaxel 68-77 kallikrein related peptidase 3 Homo sapiens 13-16 25043536-9 2014 In response to docetaxel treatment, KLK3 levels decreased in 80% (95% CI 60-100%), PCA3 in 89% (95% CI 68-100%), and TMPRSS2-ERG in 86% (95% CI 60-100%) of patients. Docetaxel 15-24 kallikrein related peptidase 3 Homo sapiens 36-40 24255983-3 2014 The percentage PSA response was recorded following first line docetaxel, abiraterone and enzalutamide treatment. Docetaxel 62-71 kallikrein related peptidase 3 Homo sapiens 15-18 25017602-5 2014 In this case report, we present a case with primary signet cell adenocarcinoma of the prostate who received docetaxel chemotherapy because of short prostate specific antigen doubling time. Docetaxel 108-117 kallikrein related peptidase 3 Homo sapiens 148-173 24725337-1 2014 BACKGROUND: A prostate-specific antigen (PSA) flare occurs in about 15% of metastatic castration-resistant prostate cancer (mCRPC) patients receiving docetaxel. Docetaxel 150-159 kallikrein related peptidase 3 Homo sapiens 14-39 24769540-3 2014 Total three studies were finally included, indicating that docetaxel plus thalidomide exhibited better survival prognosis and greater prostate-specific antigen (PSA) decline than docetaxel alone. Docetaxel 59-68 kallikrein related peptidase 3 Homo sapiens 134-165 24026658-0 2013 Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy. Docetaxel 149-158 kallikrein related peptidase 3 Homo sapiens 8-33 24742323-10 2014 Median PSA levels at DTX initiation was 20 ng/mL. Docetaxel 21-24 kallikrein related peptidase 3 Homo sapiens 7-10 24026658-0 2013 Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy. Docetaxel 149-158 kallikrein related peptidase 3 Homo sapiens 35-38 24026658-4 2013 The aim of our study was to find prostate specific antigen (PSA) characteristics that predict a shorter disease response to docetaxel chemotherapy. Docetaxel 124-133 kallikrein related peptidase 3 Homo sapiens 33-58 24026658-4 2013 The aim of our study was to find prostate specific antigen (PSA) characteristics that predict a shorter disease response to docetaxel chemotherapy. Docetaxel 124-133 kallikrein related peptidase 3 Homo sapiens 60-63 24101043-1 2013 PURPOSE: Prostate-specific antigen (PSA) kinetics, and more specifically a >= 30% decline in PSA within 3 months after initiation of first-line chemotherapy with docetaxel, are associated with improvement in overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel 165-174 kallikrein related peptidase 3 Homo sapiens 9-40 23955552-5 2013 Patients had a DTX holiday when the prostate-specific antigen (PSA) level declined >=50%. Docetaxel 15-18 kallikrein related peptidase 3 Homo sapiens 36-67 23955552-6 2013 DTX was restarted in patients with a PSA increase >=25%. Docetaxel 0-3 kallikrein related peptidase 3 Homo sapiens 37-40 24101043-1 2013 PURPOSE: Prostate-specific antigen (PSA) kinetics, and more specifically a >= 30% decline in PSA within 3 months after initiation of first-line chemotherapy with docetaxel, are associated with improvement in overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel 165-174 kallikrein related peptidase 3 Homo sapiens 36-39 22688162-12 2013 CONCLUSIONS: The low-dose combination of docetaxel, estramustine and dexamethasone is active and tolerable with beneficial effects on serum PSA levels, performance status, anemia and bone pain in Japanese patients with CRPC. Docetaxel 41-50 kallikrein related peptidase 3 Homo sapiens 140-143 22729777-6 2012 Following docetaxel-based chemotherapy, PSA declined in 118 patients (74.3%), including 87 (54.6%) achieving a PSA decline>=50%, and the median progression-free survival and overall survival (OS) were 2.9 and 23.2 months, respectively. Docetaxel 10-19 kallikrein related peptidase 3 Homo sapiens 40-43 24223414-13 2013 Declines in serum PSA levels of at least 50% occurred more frequently after treatment with docetaxel than with other chemo-agents regardless of second-and third-line chemotherapy. Docetaxel 91-100 kallikrein related peptidase 3 Homo sapiens 18-21 24223414-14 2013 Even in third-line chemothrapy, docetaxel maintained the PSA response rate, whereas the PSA response rate of other agents, including mitoxantrone, decreased in patients in whom prior therapy failed. Docetaxel 32-41 kallikrein related peptidase 3 Homo sapiens 57-60 22889368-5 2012 It shows that PSA response to first-line chemotherapy may provide a rational indication for docetaxel rechallenge. Docetaxel 92-101 kallikrein related peptidase 3 Homo sapiens 14-17 22889368-6 2012 OBJECTIVE: To determine whether prostate-specific antigen (PSA) response at first-line chemotherapy with docetaxel correlates with PSA response and survival at docetaxel rechallenge in patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel 108-117 kallikrein related peptidase 3 Homo sapiens 35-66 22889368-6 2012 OBJECTIVE: To determine whether prostate-specific antigen (PSA) response at first-line chemotherapy with docetaxel correlates with PSA response and survival at docetaxel rechallenge in patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel 108-117 kallikrein related peptidase 3 Homo sapiens 62-65 22889368-6 2012 OBJECTIVE: To determine whether prostate-specific antigen (PSA) response at first-line chemotherapy with docetaxel correlates with PSA response and survival at docetaxel rechallenge in patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel 163-172 kallikrein related peptidase 3 Homo sapiens 35-66 22889368-6 2012 OBJECTIVE: To determine whether prostate-specific antigen (PSA) response at first-line chemotherapy with docetaxel correlates with PSA response and survival at docetaxel rechallenge in patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel 163-172 kallikrein related peptidase 3 Homo sapiens 62-65 22889368-16 2012 CONCLUSION: In the present single-institution study, a reduction in PSA level of >=50% at first-line chemotherapy with docetaxel correlated with superior PSA-PFS and OS in the rechallenge setting and might, therefore, present a rational indication for docetaxel rechallenge. Docetaxel 125-134 kallikrein related peptidase 3 Homo sapiens 71-74 22889368-16 2012 CONCLUSION: In the present single-institution study, a reduction in PSA level of >=50% at first-line chemotherapy with docetaxel correlated with superior PSA-PFS and OS in the rechallenge setting and might, therefore, present a rational indication for docetaxel rechallenge. Docetaxel 125-134 kallikrein related peptidase 3 Homo sapiens 160-163 22889368-16 2012 CONCLUSION: In the present single-institution study, a reduction in PSA level of >=50% at first-line chemotherapy with docetaxel correlated with superior PSA-PFS and OS in the rechallenge setting and might, therefore, present a rational indication for docetaxel rechallenge. Docetaxel 258-267 kallikrein related peptidase 3 Homo sapiens 71-74 22889368-16 2012 CONCLUSION: In the present single-institution study, a reduction in PSA level of >=50% at first-line chemotherapy with docetaxel correlated with superior PSA-PFS and OS in the rechallenge setting and might, therefore, present a rational indication for docetaxel rechallenge. Docetaxel 258-267 kallikrein related peptidase 3 Homo sapiens 160-163 21907635-7 2011 The analysis demonstrates a higher PSA response rate from docetaxel-based combinations when compared with docetaxel alone (relative risk [RR] = 1.16; P = .010). Docetaxel 58-67 kallikrein related peptidase 3 Homo sapiens 35-38 22771826-7 2012 Docetaxel resulted in a prostate-specific antigen (PSA) decline of >=50% in nine patients [26%, 95% confidence interval (CI) 13% to 43%], with a median time to PSA progression of 4.6 months (95% CI 4.2% to 5.9%). Docetaxel 0-9 kallikrein related peptidase 3 Homo sapiens 24-55 22771826-7 2012 Docetaxel resulted in a prostate-specific antigen (PSA) decline of >=50% in nine patients [26%, 95% confidence interval (CI) 13% to 43%], with a median time to PSA progression of 4.6 months (95% CI 4.2% to 5.9%). Docetaxel 0-9 kallikrein related peptidase 3 Homo sapiens 51-54 22369348-0 2012 Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer. Docetaxel 150-159 kallikrein related peptidase 3 Homo sapiens 0-25 22369348-5 2012 The present study showed that PSA response to deferred CAB therapy predicts clinical outcomes after subsequent oestrogen and docetaxel therapy. Docetaxel 125-134 kallikrein related peptidase 3 Homo sapiens 30-33 22369348-17 2012 CONCLUSION: PSA response to deferred CAB predicts clinical outcomes after subsequent oestrogen and docetaxel therapies in patients with CRPC, and provides useful information for planning individualized optimum treatment courses that include secondary hormonal therapy and chemotherapy. Docetaxel 99-108 kallikrein related peptidase 3 Homo sapiens 12-15 22369480-1 2012 Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer. Docetaxel 150-159 kallikrein related peptidase 3 Homo sapiens 0-25 22287756-11 2012 Second-line treatment with docetaxel in nine patients induced a normalisation in PSA level in two (22%). Docetaxel 27-36 kallikrein related peptidase 3 Homo sapiens 81-84 22287756-16 2012 Normalisation of PSA during first-line treatment with docetaxel is associated with a better survival irrespective of second- or further-line treatment used. Docetaxel 54-63 kallikrein related peptidase 3 Homo sapiens 17-20 22343736-5 2012 Prognostic factors on PSA progression were PSA value before DTX treatment and rate of PSA decrement after DTX treatment. Docetaxel 60-63 kallikrein related peptidase 3 Homo sapiens 22-25 22343736-5 2012 Prognostic factors on PSA progression were PSA value before DTX treatment and rate of PSA decrement after DTX treatment. Docetaxel 106-109 kallikrein related peptidase 3 Homo sapiens 22-25 22343736-7 2012 Odds ratio of PSA 20 ng/ml before DTX treatment was 2.99 and PSA decreasing rate < 30% was 3.65. Docetaxel 35-38 kallikrein related peptidase 3 Homo sapiens 14-17 22282219-13 2012 CONCLUSIONS: Neoadjuvant docetaxel and bevacizumab is safe, and results in reductions in both tumor volume and serum PSA, in men with high-risk localized prostate cancer. Docetaxel 25-34 kallikrein related peptidase 3 Homo sapiens 117-120 21907635-7 2011 The analysis demonstrates a higher PSA response rate from docetaxel-based combinations when compared with docetaxel alone (relative risk [RR] = 1.16; P = .010). Docetaxel 106-115 kallikrein related peptidase 3 Homo sapiens 35-38 20230389-4 2010 The primary objective was to assess efficacy in terms of the prostate-specific antigen (PSA) response after resuming a docetaxel-based chemotherapy. Docetaxel 119-128 kallikrein related peptidase 3 Homo sapiens 61-92 21915752-8 2011 Meta-analysis showed that there was significant improvement in PSA response rate in docetaxel-based therapy with estramustine group, compared with docetaxel-based therapy group (OR = 1.55, 95% CI = 1.10-2.18, P = 0.012). Docetaxel 84-93 kallikrein related peptidase 3 Homo sapiens 63-66 21915752-8 2011 Meta-analysis showed that there was significant improvement in PSA response rate in docetaxel-based therapy with estramustine group, compared with docetaxel-based therapy group (OR = 1.55, 95% CI = 1.10-2.18, P = 0.012). Docetaxel 147-156 kallikrein related peptidase 3 Homo sapiens 63-66 21256546-5 2011 Docetaxel was resumed at a >25% prostate-specific antigen increase from the nadir level, also confirmed by a second measurement 4 weeks later, or in cases of documented disease progression. Docetaxel 0-9 kallikrein related peptidase 3 Homo sapiens 35-60 20230389-9 2010 After docetaxel reintroduction, 24 patients (48%) had a 50% decrease in PSA level (95% confidence interval, CI, 34.1-61.8%). Docetaxel 6-15 kallikrein related peptidase 3 Homo sapiens 72-75 19826044-3 2009 Here, we showed that treatment of 22Rv1, a PTEN-positive CRPC cell line, with paclitaxel and its semisynthetic analogue docetaxel decreases expression of the androgen receptor (AR)-activated genes prostate-specific antigen (PSA) and Nkx3.1 but increases expression of the AR repression gene maspin, suggesting that Taxol treatment inhibits AR activity. Docetaxel 120-129 kallikrein related peptidase 3 Homo sapiens 197-228 19917571-1 2010 BACKGROUND: Docetaxel (Taxotere) improve survival and prostate-specific antigen (PSA) response rates in patients with metastatic castrate-resistant prostate cancer (CRPC). Docetaxel 12-21 kallikrein related peptidase 3 Homo sapiens 54-85 19917571-1 2010 BACKGROUND: Docetaxel (Taxotere) improve survival and prostate-specific antigen (PSA) response rates in patients with metastatic castrate-resistant prostate cancer (CRPC). Docetaxel 23-31 kallikrein related peptidase 3 Homo sapiens 54-85 20404974-5 2010 The main reasons for initiating docetaxel were rising prostate-specific antigen (PSA, 98%) and progressive symptoms (77%). Docetaxel 32-41 kallikrein related peptidase 3 Homo sapiens 54-89 19920389-0 2009 Decrease in prostate specific antigen secretion correlated with docetaxel-induced growth inhibition and apoptosis in human prostate tumor cells. Docetaxel 64-73 kallikrein related peptidase 3 Homo sapiens 12-37 19920389-6 2009 In docetaxel-treated LNCaP cells,there was a linear correlation between growth inhibition and the decline in PSA level in the culture medium. Docetaxel 3-12 kallikrein related peptidase 3 Homo sapiens 109-112 19920389-7 2009 It was demonstrated that docetaxel had potent antitumor activity against human prostate tumor cells,and the decrease in cell growth was associated with a decrease in PSA secretion,suggesting that PSA would be a useful biological marker for monitoring the efficacy of docetaxel in a clinical setting. Docetaxel 25-34 kallikrein related peptidase 3 Homo sapiens 196-199 19920389-7 2009 It was demonstrated that docetaxel had potent antitumor activity against human prostate tumor cells,and the decrease in cell growth was associated with a decrease in PSA secretion,suggesting that PSA would be a useful biological marker for monitoring the efficacy of docetaxel in a clinical setting. Docetaxel 267-276 kallikrein related peptidase 3 Homo sapiens 166-169 19920389-7 2009 It was demonstrated that docetaxel had potent antitumor activity against human prostate tumor cells,and the decrease in cell growth was associated with a decrease in PSA secretion,suggesting that PSA would be a useful biological marker for monitoring the efficacy of docetaxel in a clinical setting. Docetaxel 267-276 kallikrein related peptidase 3 Homo sapiens 196-199 18990177-0 2008 Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. Docetaxel 48-57 kallikrein related peptidase 3 Homo sapiens 0-25 19829727-0 2009 A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. Docetaxel 32-41 kallikrein related peptidase 3 Homo sapiens 8-11 19575420-0 2009 Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Docetaxel 0-9 kallikrein related peptidase 3 Homo sapiens 65-90 19575420-0 2009 Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Docetaxel 0-9 kallikrein related peptidase 3 Homo sapiens 182-185 19575420-5 2009 The effect of DOC on PSA levels of LNCaP and MDA-PCa-2b cells was also measured in conditioned media. Docetaxel 14-17 kallikrein related peptidase 3 Homo sapiens 21-24 19575420-8 2009 Unexpectedly, we found DOC significantly down-regulated both AR and PSA in a dose-dependent manner in the cell lines studied. Docetaxel 23-26 kallikrein related peptidase 3 Homo sapiens 68-71 19297314-5 2009 RESULTS: Confirmed PSA response was observed in 46% and 37% of 57 and 54 patients treated with docetaxel and docetaxel-oblimersen, respectively. Docetaxel 95-104 kallikrein related peptidase 3 Homo sapiens 19-22 19297314-5 2009 RESULTS: Confirmed PSA response was observed in 46% and 37% of 57 and 54 patients treated with docetaxel and docetaxel-oblimersen, respectively. Docetaxel 109-118 kallikrein related peptidase 3 Homo sapiens 19-22 19230915-1 2009 PURPOSE: Taxane based chemotherapy has activity in advanced prostate cancer but previous studies of neoadjuvant docetaxel demonstrated a prostate specific antigen response with no obvious antitumor activity. Docetaxel 112-121 kallikrein related peptidase 3 Homo sapiens 137-162 19513599-10 2009 Patients with a decline of PSA under docetaxel and MP had a progression-free survival of 11.5 months (median). Docetaxel 37-46 kallikrein related peptidase 3 Homo sapiens 27-30 18990177-1 2008 OBJECTIVE: To evaluate the prostate-specific antigen (PSA) "flare" phenomenon in patients with androgen-independent prostate cancer (AIPC) treated with docetaxel, as flare is a known effect of androgen-deprivation therapy in hormone-dependent prostate cancer. Docetaxel 152-161 kallikrein related peptidase 3 Homo sapiens 27-58 18990177-5 2008 There was also a fourth response, i.e. PSA flare, defined as an increase in PSA level with no symptomatic progression, after starting docetaxel-based chemotherapy administered every 3 weeks. Docetaxel 134-143 kallikrein related peptidase 3 Homo sapiens 39-42 18990177-13 2008 CONCLUSION: Of patients with AIPC, 14% had an initial PSA flare after starting docetaxel-based chemotherapy. Docetaxel 79-88 kallikrein related peptidase 3 Homo sapiens 54-57 18382240-5 2008 Declines in serum prostate-specific antigen levels may be modest surrogates of response to cytotoxic agents such as docetaxel, but have not been validated for agents with novel mechanisms of action, such as antiangiogenic, immunologic, or cytostatic drugs. Docetaxel 116-125 kallikrein related peptidase 3 Homo sapiens 18-43 18794543-7 2008 PSA of less than 4 ng/mL occurred in 29 (41%) of 71 patients receiving D/E and in 17 (25%) of 69 patients receiving D (P = .05). Docetaxel 71-72 kallikrein related peptidase 3 Homo sapiens 0-3 18276061-6 2008 Seven major PSA responses were recorded in the same patients who had reported a >50% PSA decrease after first-line docetaxel. Docetaxel 118-127 kallikrein related peptidase 3 Homo sapiens 12-15 18276061-6 2008 Seven major PSA responses were recorded in the same patients who had reported a >50% PSA decrease after first-line docetaxel. Docetaxel 118-127 kallikrein related peptidase 3 Homo sapiens 88-91 18276061-7 2008 However, four major PSA responses were observed in patients previously nonresponsive to docetaxel alone. Docetaxel 88-97 kallikrein related peptidase 3 Homo sapiens 20-23 18487550-9 2008 Data on PSA response are available for 96 patients: PSA response (> or =50% reduction) occurred in 15% of 71 men receiving mitoxantrone after docetaxel and in 28% of 25 men receiving docetaxel after mitoxantrone. Docetaxel 145-154 kallikrein related peptidase 3 Homo sapiens 52-55 18487550-9 2008 Data on PSA response are available for 96 patients: PSA response (> or =50% reduction) occurred in 15% of 71 men receiving mitoxantrone after docetaxel and in 28% of 25 men receiving docetaxel after mitoxantrone. Docetaxel 186-195 kallikrein related peptidase 3 Homo sapiens 52-55 18487550-12 2008 The PSA response rate to docetaxel after mitoxantrone was higher than that for mitoxantrone after docetaxel. Docetaxel 25-34 kallikrein related peptidase 3 Homo sapiens 4-7 18510661-7 2008 CONCLUSION: Docetaxel was associated with high rates of PSA and pain response in this study. Docetaxel 12-21 kallikrein related peptidase 3 Homo sapiens 56-59 18565882-11 2008 Increasing the number of docetaxel cycles after a shorter period of testosterone repletion, and a longer duration of testosterone depletion, increased the proportion of men who achieved an undetectable PSA. Docetaxel 25-34 kallikrein related peptidase 3 Homo sapiens 202-205 18307687-7 2008 A PSA decline of > or 1=30% within 3 months" therapy with docetaxel is also a surrogate of OS. Docetaxel 61-70 kallikrein related peptidase 3 Homo sapiens 2-5 17602304-1 2008 OBJECTIVES: The intention of this study is to describe the impact and underlying potential basis of the prostate-specific antigen (PSA) flare-up phenomenon in patients with hormone-refractory prostate cancer (HRPC) treated with docetaxel-based chemotherapy. Docetaxel 228-237 kallikrein related peptidase 3 Homo sapiens 104-135 17998285-0 2008 Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Docetaxel 161-170 kallikrein related peptidase 3 Homo sapiens 87-90 17445976-8 2008 CONCLUSIONS: Among patients with AIPC treated with biweekly docetaxel and estramustine, baseline PSA >100, existence of pain, weight loss, and simultaneous extraosseous and bone disease were associated with worse prognosis. Docetaxel 60-69 kallikrein related peptidase 3 Homo sapiens 97-100 18095916-3 2008 In a Phase II trial in men with hormone refractory prostate cancer, DMXAA (ASA404) in combination with docetaxel achieved a prostate-specific antigen response in more patients than docetaxel therapy alone, and was generally well tolerated. Docetaxel 103-112 kallikrein related peptidase 3 Homo sapiens 124-149 17639587-18 2007 CONCLUSIONS: The combination of diethylstilbestrol and docetaxel produces a significant level of activity, measured by PSA decline and measurable disease response rate, and except for venous thrombosis the toxicity appears similar to that seen with docetaxel plus prednisone. Docetaxel 55-64 kallikrein related peptidase 3 Homo sapiens 119-122 17575225-9 2007 Detectable IGF-IR expression on CTCs before treatment with CP-751,871 and docetaxel was associated with a higher frequency of prostate-specific antigen decline by >50% (6 of 10 versus 2 of 8 patients). Docetaxel 74-83 kallikrein related peptidase 3 Homo sapiens 126-151 17673473-8 2007 CONCLUSION: A regimen of docetaxel q3w with PSL daily was associated with a high rate of PSA reduction and prolongation of patient survival. Docetaxel 25-34 kallikrein related peptidase 3 Homo sapiens 89-92 17825143-11 2007 CONCLUSION: Docetaxel plus prednisone for the treatment of HRPC can delay the progression of the disease, decrease the PSA value, diminish the lymph node, ease the pain, improve the quality of live, and the tolerance is quite good. Docetaxel 12-21 kallikrein related peptidase 3 Homo sapiens 119-122 16940810-0 2006 Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. Docetaxel 132-141 kallikrein related peptidase 3 Homo sapiens 27-52 17270637-10 2007 CONCLUSIONS: The results of this study have suggested the feasibility and tolerability of the combination of weekly docetaxel and weekly epirubicin, which led to a rapid and long-lasting decrease in prostate-specific antigen levels and a palliative response in patients with advanced hormone-refractory prostate cancer. Docetaxel 116-125 kallikrein related peptidase 3 Homo sapiens 199-224 17135641-0 2006 Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. Docetaxel 0-9 kallikrein related peptidase 3 Homo sapiens 72-97 16940810-3 2006 The aim of this study was to evaluate the clinical impact of a prostate-specific antigen flare phenomenon in docetaxel-treated hormone-refractory prostate cancer patients. Docetaxel 109-118 kallikrein related peptidase 3 Homo sapiens 63-88 16940810-15 2006 Thus, an initial rise of prostate-specific antigen under docetaxel therapy in hormone-refractory prostate cancer does not indicate therapeutic failure and should not lead to early withdrawal from therapy in the absence of clinical signs of progression. Docetaxel 57-66 kallikrein related peptidase 3 Homo sapiens 25-50 16033841-10 2005 CONCLUSIONS: Neoadjuvant docetaxel administered for 6 months before radical prostatectomy is feasible, well tolerated, and often results in prostate-specific antigen declines of >50% and decreased tumor volume on endorectal MRI. Docetaxel 25-34 kallikrein related peptidase 3 Homo sapiens 140-165 16685278-8 2006 The amplitudes of docetaxel-induced increases were associated with baseline prostate-specific antigen (PSA) and CK18 serum levels in these patients, consistent with tumoral origin of caspase-cleaved fragments. Docetaxel 18-27 kallikrein related peptidase 3 Homo sapiens 76-107 16456811-9 2006 Second-line docetaxel produced a higher PSA response compared with mitoxantrone (38% vs. 12%, P = 0.012), but this did not translate to a survival benefit. Docetaxel 12-21 kallikrein related peptidase 3 Homo sapiens 40-43 16729913-0 2006 Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Docetaxel 7-16 kallikrein related peptidase 3 Homo sapiens 74-100 16729913-3 2006 This phase II study was performed as a preliminary evaluation of the feasibility and efficacy of weekly docetaxel/estramustine in patients with prostate cancer and increasing serum PSA levels. Docetaxel 104-113 kallikrein related peptidase 3 Homo sapiens 181-184 16729913-12 2006 CONCLUSION: Treatment with weekly docetaxel and estramustine is feasible and active in patients with prostate cancer and increasing serum PSA levels. Docetaxel 34-43 kallikrein related peptidase 3 Homo sapiens 138-141 15939076-3 2005 Docetaxel demonstrated clinical activity in HRPC on weekly and every-3-weeks schedules as evidenced by decreases in prostate-specific antigen (PSA) values that were higher than those traditionally seen with other chemotherapy regimens. Docetaxel 0-9 kallikrein related peptidase 3 Homo sapiens 116-147 15939077-8 2005 Significantly more patients treated with docetaxel-estramustine had a prostate-specific antigen response decline of at least 50% compared with those treated with mitoxantrone-prednisone (50% vs 27%, P < .001). Docetaxel 41-50 kallikrein related peptidase 3 Homo sapiens 70-95 15869727-5 2005 Prostate-specific antigen levels dropped by more than 50% in 38% to 48% of patients treated with docetaxel. Docetaxel 97-106 kallikrein related peptidase 3 Homo sapiens 0-25 15738531-0 2005 Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. Docetaxel 10-19 kallikrein related peptidase 3 Homo sapiens 55-80 15738531-1 2005 PURPOSE: To evaluate docetaxel in the treatment of patients with early-stage prostate cancer with prostate-specific antigen (PSA) progression after local therapy without androgen ablation therapy. Docetaxel 21-30 kallikrein related peptidase 3 Homo sapiens 98-129 15738531-13 2005 CONCLUSION: This study demonstrated the activity of docetaxel alone, without androgen ablation, in patients with PSA progression after completion of local therapy. Docetaxel 52-61 kallikrein related peptidase 3 Homo sapiens 113-116 15738542-7 2005 A > or = 50% PSA decline was found in a greater percentage of patients in the docetaxel arms (67% and 63%) compared with MP (18%; P = .0001). Docetaxel 81-90 kallikrein related peptidase 3 Homo sapiens 16-19 15467765-5 2004 We prospectively tested intermittent chemotherapy in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) <4 ng ml(-1) (22% of the 37 patients who were initially treated with this regimen). Docetaxel 103-112 kallikrein related peptidase 3 Homo sapiens 133-164 15837994-0 2005 Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. Docetaxel 0-9 kallikrein related peptidase 3 Homo sapiens 69-94 15837994-2 2005 The purpose of this study was to determine feasibility, tolerability, and outcome of docetaxel followed by hormone therapy in men experiencing an increasing prostate-specific antigen (PSA) after their primary local treatments for PC. Docetaxel 85-94 kallikrein related peptidase 3 Homo sapiens 157-188 15780173-4 2005 RESULTS: In the TAX 327 trial, 3-weekly docetaxel plus prednisone proved significantly superior to mitoxantrone plus prednisone (an established reference regimen) in extending survival, reducing levels of prostate specific antigen (PSA), controlling pain and improving quality of life. Docetaxel 40-49 kallikrein related peptidase 3 Homo sapiens 205-230 15780173-4 2005 RESULTS: In the TAX 327 trial, 3-weekly docetaxel plus prednisone proved significantly superior to mitoxantrone plus prednisone (an established reference regimen) in extending survival, reducing levels of prostate specific antigen (PSA), controlling pain and improving quality of life. Docetaxel 40-49 kallikrein related peptidase 3 Homo sapiens 232-235 15780173-7 2005 Men treated with the docetaxel regimen were also more likely to have a PSA response. Docetaxel 21-30 kallikrein related peptidase 3 Homo sapiens 71-74 16266195-5 2005 Compared with mitoxantrone plus prednisone, docetaxel plus prednisone improved prostate specific antigen response rate, pain and health-related quality of life, and docetaxel plus estramustine increased progression-free survival. Docetaxel 44-53 kallikrein related peptidase 3 Homo sapiens 79-104 15732332-8 2005 Combination chemotherapy with docetaxel and cisplatin in patients with HRPC was well tolerated and efficatious with a significant decrease in serum PSA and measurable disease. Docetaxel 30-39 kallikrein related peptidase 3 Homo sapiens 148-151 15934892-5 2005 When given with prednisone, docetaxel was also shown to reduce pain and serum prostate specific antigen levels and improve quality of life compared with mitoxantrone/prednisone. Docetaxel 28-37 kallikrein related peptidase 3 Homo sapiens 78-103 15945343-5 2005 One recent phase III trial showed that docetaxel (Taxotere)/ estramustine (Emcyt) significantly improved overall survival, progression-free survival, and PSA response rate compared with mitoxantrone (Novantrone) plus prednisone. Docetaxel 39-48 kallikrein related peptidase 3 Homo sapiens 154-157 15945343-5 2005 One recent phase III trial showed that docetaxel (Taxotere)/ estramustine (Emcyt) significantly improved overall survival, progression-free survival, and PSA response rate compared with mitoxantrone (Novantrone) plus prednisone. Docetaxel 50-58 kallikrein related peptidase 3 Homo sapiens 154-157 15945343-6 2005 Another phase III trial demonstrated that docetaxel given every 3 weeks plus prednisone significantly improved overall survival, PSA response rate, pain relief response rate, and quality of life compared with mitoxantrone and prednisone. Docetaxel 42-51 kallikrein related peptidase 3 Homo sapiens 129-132 15470213-11 2004 CONCLUSIONS: When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plus prednisone. Docetaxel 56-65 kallikrein related peptidase 3 Homo sapiens 164-167 15150548-3 2004 Treatment with docetaxel or paclitaxel, with or without estramustine, appears to convey higher rates of prostate-specific antigen response in phase II trials, but is more toxic. Docetaxel 15-24 kallikrein related peptidase 3 Homo sapiens 104-129 15183967-8 2004 A statistically significant reduction in the prechemotherapy versus postchemotherapy mean PSA level was observed (12.00 +/- 1.86 ng/mL versus 8.42 +/- 1.63 ng/mL, P <0.03), with 79% of patients experiencing some reduction and 24% a more than 50% reduction in PSA level in response to docetaxel alone. Docetaxel 287-296 kallikrein related peptidase 3 Homo sapiens 90-93 15329105-12 2004 CONCLUSION: Docetaxel-zoledronic acid therapy is safe and decreased the serum PSA by more than half at 2 months in more than half the patients. Docetaxel 12-21 kallikrein related peptidase 3 Homo sapiens 78-81 15226321-5 2004 RESULTS: After a median potential follow-up time of 26.4 months, the proportion of patients with a greater than 50% decline in PSA was higher in the docetaxel/thalidomide group (53% in the combined group, 37% in docetaxel-alone arm). Docetaxel 149-158 kallikrein related peptidase 3 Homo sapiens 127-130 15226321-9 2004 CONCLUSION: In this randomized phase II trial, the addition of thalidomide to docetaxel resulted in an encouraging PSA decline rate and overall median survival rate in patients with metastatic AIPC. Docetaxel 78-87 kallikrein related peptidase 3 Homo sapiens 115-118 14532760-5 2003 RESULTS: Docetaxel, which acts primarily by inhibiting microtubular depolymerization, in combination with other agents has consistently demonstrated a palliative response, a decrease in serum prostate specific antigen levels by 50% or greater in more than 60% of patients, a decrease in measurable disease and the suggestion of improved survival. Docetaxel 9-18 kallikrein related peptidase 3 Homo sapiens 192-217 15218295-16 2004 CONCLUSION: Weekly docetaxel at a dosage of 40 mg/m(2) is a well-tolerated treatment, which has very promising activity on the reduction of PSA in metastatic HRPC. Docetaxel 19-28 kallikrein related peptidase 3 Homo sapiens 140-143 15078909-10 2004 CONCLUSIONS: Weekly administration of docetaxel as a single agent was associated with a high rate of PSA reduction. Docetaxel 38-47 kallikrein related peptidase 3 Homo sapiens 101-104 10687988-6 2000 On estramustine and docetaxel therapy PSA decreased 50% or greater in 11 patients (92%, 95% confidence intervals [CI] 60 to 99) and 80% or greater in 7 (58%, 95% CI 29 to 84), and normalized in 5 (42%, 95% CI 16 to 71), with a median duration of response of 153 (range 42 to 371), 132 (range 84 to 287) and 84 (range 21 to 174) days, respectively. Docetaxel 20-29 kallikrein related peptidase 3 Homo sapiens 38-41 16985946-5 2003 Study results showed that 75% of patients had reductions in prostate-specific antigen (PSA) levels ranging from 9%-79% at the completion of docetaxel therapy. Docetaxel 140-149 kallikrein related peptidase 3 Homo sapiens 60-91 16986042-5 2003 Study results showed that 75% of patients had reductions in prostate-specific antigen (PSA) levels ranging from 9%-79% at the completion of docetaxel therapy. Docetaxel 140-149 kallikrein related peptidase 3 Homo sapiens 60-91 15046690-10 2002 The other 2 trials are exploring the PSA vaccine with docetaxel and the combination of docetaxel with ketoconazole. Docetaxel 54-63 kallikrein related peptidase 3 Homo sapiens 37-40 12966410-2 2003 We prospectively tested this approach in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) <4 ng ml(-1). Docetaxel 91-100 kallikrein related peptidase 3 Homo sapiens 121-152 11685723-11 2001 Single-agent docetaxel at 36 mg/m(2) weekly was associated with a PSA response rate of 41%, increased time to progression and survival, and minimal myelosuppression in patients with hormone-refractory metastatic prostate cancer. Docetaxel 13-22 kallikrein related peptidase 3 Homo sapiens 66-69 11685725-7 2001 Thus, the preliminary results suggest that docetaxel before hormonal therapy includes a PSA response in many prostate cancer patients with biochemical failure after definitive local therapies. Docetaxel 43-52 kallikrein related peptidase 3 Homo sapiens 88-91 11685728-8 2001 Reductions in prostate-specific antigen levels were noted in seven of 10 patients who completed the 6-week course of neoadjuvant docetaxel. Docetaxel 129-138 kallikrein related peptidase 3 Homo sapiens 14-39 11685729-10 2001 All 5 patients who had completed 8 weeks of calcitriol/docetaxel treatment achieved prostate-specific antigen (PSA) reductions of > or =50%. Docetaxel 55-64 kallikrein related peptidase 3 Homo sapiens 84-115 11685730-1 2001 Single-agent docetaxel has been shown to produce a significant decrease in prostate-specific antigen (PSA) levels among patients with hormone-refractory prostate cancer (HRPC). Docetaxel 13-22 kallikrein related peptidase 3 Homo sapiens 75-106 35197069-2 2022 Patients receiving androgen deprivation therapy along with docetaxel result in superior survival, lower serum prostate specific antigen (PSA) level, and better quality of life. Docetaxel 59-68 kallikrein related peptidase 3 Homo sapiens 110-135 34549837-6 2022 Pretreatment prostate-specific antigen levels and time to castration-resistant prostate cancer were differentially associated with progression-free survival and overall survival between androgen receptor pathway inhibitor or docetaxel. Docetaxel 225-234 kallikrein related peptidase 3 Homo sapiens 13-38 35314092-1 2022 AIMS: We conducted a pooled analysis of four randomised controlled trials and a non-trial retrospective dataset to study the changes in serum prostate-specific antigen (PSA) concentrations during treatment and its impact on survival in men treated with docetaxel for metastatic castration-resistant prostate cancer. Docetaxel 253-262 kallikrein related peptidase 3 Homo sapiens 142-167 35314092-1 2022 AIMS: We conducted a pooled analysis of four randomised controlled trials and a non-trial retrospective dataset to study the changes in serum prostate-specific antigen (PSA) concentrations during treatment and its impact on survival in men treated with docetaxel for metastatic castration-resistant prostate cancer. Docetaxel 253-262 kallikrein related peptidase 3 Homo sapiens 169-172 35197069-2 2022 Patients receiving androgen deprivation therapy along with docetaxel result in superior survival, lower serum prostate specific antigen (PSA) level, and better quality of life. Docetaxel 59-68 kallikrein related peptidase 3 Homo sapiens 137-140 33981608-7 2021 Triptorelin, bicalutamide, zoledronic acid, and docetaxel were then administered, six cycles later, the metastatic tumors in the lungs disappeared and those in the bones lessened significantly, along with a remarkable reduction in PSA level (< 2 ng/ml). Docetaxel 48-57 kallikrein related peptidase 3 Homo sapiens 231-234 34043207-0 2021 Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival. Docetaxel 9-18 kallikrein related peptidase 3 Homo sapiens 141-144 34043207-1 2021 INTRODUCTION: This study aimed to assess the effects of multiple docetaxel (DOC) treatments on prostate-specific antigen (PSA) kinetics and survival among patients with metastatic castration-resistant prostate cancer (mCRPC) who were sensitive to first-line DOC and received no other life-prolonging agents. Docetaxel 65-74 kallikrein related peptidase 3 Homo sapiens 95-120 34043207-1 2021 INTRODUCTION: This study aimed to assess the effects of multiple docetaxel (DOC) treatments on prostate-specific antigen (PSA) kinetics and survival among patients with metastatic castration-resistant prostate cancer (mCRPC) who were sensitive to first-line DOC and received no other life-prolonging agents. Docetaxel 65-74 kallikrein related peptidase 3 Homo sapiens 122-125 34043207-1 2021 INTRODUCTION: This study aimed to assess the effects of multiple docetaxel (DOC) treatments on prostate-specific antigen (PSA) kinetics and survival among patients with metastatic castration-resistant prostate cancer (mCRPC) who were sensitive to first-line DOC and received no other life-prolonging agents. Docetaxel 76-79 kallikrein related peptidase 3 Homo sapiens 95-120 34043207-1 2021 INTRODUCTION: This study aimed to assess the effects of multiple docetaxel (DOC) treatments on prostate-specific antigen (PSA) kinetics and survival among patients with metastatic castration-resistant prostate cancer (mCRPC) who were sensitive to first-line DOC and received no other life-prolonging agents. Docetaxel 76-79 kallikrein related peptidase 3 Homo sapiens 122-125 33904646-9 2021 IMPLICATIONS FOR PRACTICE: Using data from the FIRSTANA and PROSELICA phase III clinical trials we demonstrate that patients with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel or cabazitaxel, who exhibited a response (pain, tumor, PSA), often experienced significantly greater improvements in health-related quality of life (HRQL) compared with patients without a response. Docetaxel 196-205 kallikrein related peptidase 3 Homo sapiens 261-264 33116879-12 2020 Conclusion: Our results indicate an association between PSA kinetics, especially early PSA response, and outcome to AA after progression to docetaxel. Docetaxel 140-149 kallikrein related peptidase 3 Homo sapiens 56-59 33116879-12 2020 Conclusion: Our results indicate an association between PSA kinetics, especially early PSA response, and outcome to AA after progression to docetaxel. Docetaxel 140-149 kallikrein related peptidase 3 Homo sapiens 87-90 31672485-0 2020 PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium. Docetaxel 55-64 kallikrein related peptidase 3 Homo sapiens 0-3 32606932-12 2020 Conclusion: ADT combined with 6 cycles of docetaxel + prednisone chemotherapy benefits patients diagnosed with high-burden mHSPC in terms of the OS, PFS of PSA and radiographic, and the ratio of PSA falling to 0.2 ng/mL. Docetaxel 42-51 kallikrein related peptidase 3 Homo sapiens 156-159 32606932-12 2020 Conclusion: ADT combined with 6 cycles of docetaxel + prednisone chemotherapy benefits patients diagnosed with high-burden mHSPC in terms of the OS, PFS of PSA and radiographic, and the ratio of PSA falling to 0.2 ng/mL. Docetaxel 42-51 kallikrein related peptidase 3 Homo sapiens 195-198 32363164-6 2020 In docetaxel-treated patients, the SMIhi group had higher PSA progression-free survival (13.5 vs. 5.9 months, p = 0.016) and radiologic progression-free survival (14.6 vs. 6.7 months, p < 0.001) than the SMIlo group. Docetaxel 3-12 kallikrein related peptidase 3 Homo sapiens 58-61 33486495-8 2020 The prostate-specific antigen progression rate, prostate cancer-specific survival, and overall survival were significantly better with >=8 cycles of docetaxel than with <8 cycles (p < 0.05). Docetaxel 149-158 kallikrein related peptidase 3 Homo sapiens 4-29 32785928-2 2020 He had progressed to first-line therapy for CRPC with abiraterone plus androgen-deprivation therapy (ADT) and as second-line therapy he was being treated with docetaxel, with biochemical progression in his last prostate specific antigen measurement. Docetaxel 159-168 kallikrein related peptidase 3 Homo sapiens 211-236 32194730-7 2020 In addition, the prostate-specific antigen response rate after docetaxel (DTX) therapy in patients with high KLG expression was lower than that in patients with low KLG expression. Docetaxel 63-72 kallikrein related peptidase 3 Homo sapiens 17-42 32194730-7 2020 In addition, the prostate-specific antigen response rate after docetaxel (DTX) therapy in patients with high KLG expression was lower than that in patients with low KLG expression. Docetaxel 74-77 kallikrein related peptidase 3 Homo sapiens 17-42 32206132-6 2020 The patient underwent docetaxel chemotherapy for treatment of prostate cancer liver metastasis and showed a favorable response to treatment by significant decreased size of the hypodense lesions in the liver on post treatment abdominal CT, along with dramatic reduction of PSA level and improvement of liver function. Docetaxel 22-31 kallikrein related peptidase 3 Homo sapiens 273-276 32091336-14 2020 Patients treated with docetaxel-estramustine had a prostate-specific antigen response decline of at least 50%. Docetaxel 22-31 kallikrein related peptidase 3 Homo sapiens 51-76 31185946-6 2019 His serum prostate-specific antigen (PSA) level decreased to < 0.01 ng/mL but gradually increased following docetaxel chemotherapy. Docetaxel 111-120 kallikrein related peptidase 3 Homo sapiens 10-41 31183025-1 2019 A 66-year-old man with a previous history of advanced prostate cancer failing complete androgen blockade, docetaxel chemotherapy, denosumab, and abiraterone acetate as judged by persistent high serum levels of prostate specific antigen presented with exertional dyspnea, normocytic anemia, and thrombocytopenia. Docetaxel 106-115 kallikrein related peptidase 3 Homo sapiens 210-235 30987844-0 2019 Re: Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients with High-risk Prostate Cancer with Rising Prostate-specific Antigen Levels After Primary Local Therapy A Randomized Clinical Trial. Docetaxel 21-30 kallikrein related peptidase 3 Homo sapiens 118-143 31098427-12 2019 Conclusions: Comparing our findings with those of the prior chemohormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer (CHAARTED) study, in Korean patients, the use of docetaxel plus ADT for mHSPC showed similar results for early oncologic outcomes including PSA response and time to clinical progression. Docetaxel 214-223 kallikrein related peptidase 3 Homo sapiens 305-308 30703190-0 2019 Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial. Docetaxel 17-26 kallikrein related peptidase 3 Homo sapiens 114-139 30703190-2 2019 Objective: To assess the benefit of ADT plus docetaxel in patients presenting with rising prostate-specific antigen (PSA) levels after primary local therapy and high-risk factors but no evidence of metastatic disease. Docetaxel 45-54 kallikrein related peptidase 3 Homo sapiens 90-121